Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02142608 · ClinicalTrials.gov registry record · Phase 1
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT02142608: Completed Phase 1 study of Prostate Cancer, sponsored by Bracco Diagnostics.
NCT02142608 is a Phase 1 study of Prostate Cancer that has completed, run by Bracco Diagnostics. The registered enrollment target is 19 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02142608, a Phase 1 study of Prostate Cancer, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results
Conditions Studied
Interventions
- DRUG BR55
Study Locations (2)
California
- Translational Molecular Imaging Lab - Stanford
Other
- Service d'Imagerie Diagnostique et Interventionnelle de l'Adulte - Bordeaux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02142608
The ClinicalTrials.gov registry entry for NCT02142608 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which BR55 is the first listed.
NCT02142608 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT02142608 about?
NCT02142608 is a clinical study titled "A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer". Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score ≥7 by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results
What is the current status of trial NCT02142608?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-08. Estimated completion is 2016-01.
What conditions does trial NCT02142608 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02142608?
The interventions under investigation include: BR55 (DRUG).
Who is sponsoring clinical trial NCT02142608?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02142608 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.